The Growing Challenge of Haematological Malignancies in Older Adults

Abstract

The rising tide of an aging population brings a surge in hematological malignancies (blood cancers) diagnosed in older adults. This review explores the unique challenges posed by these cancers in this age group. We delve into the changing epidemiology of blood cancers with age, focusing on common types like leukemia, lymphoma, and myeloma. We discuss the importance of geriatric assessment to evaluate an older adult's fitness for treatment and identify potential vulnerabilities. Finally, we explore treatment considerations, balancing efficacy with potential toxicities to optimize outcomes for this vulnerable population.

Introduction

Hematological malignancies, encompassing cancers of the blood, bone marrow, and lymphatic system, pose a significant health threat. However, the landscape of these cancers shifts dramatically with age. This review sheds light on the growing challenge of hematological malignancies in older adults.

Epidemiology: Blood Cancers and Age

The incidence of most blood cancers rises sharply with advancing age. Here's a breakdown of common types:

• Leukemia: Acute myeloid leukemia (AML) is the most frequent leukemia in older adults, while the incidence of acute lymphoblastic leukemia (ALL) remains stable.

• Lymphoma: Non-Hodgkin lymphoma (NHL) is the most common lymphoma diagnosed in older adults.

• Myeloma: The risk of developing multiple myeloma increases significantly with age.

Geriatric Assessment: A Crucial Step

Older adults often present with multiple medical conditions and functional limitations. Geriatric assessment plays a critical role in:

• Identifying age-related vulnerabilities: This assessment evaluates physical fitness, cognitive function, and social support systems.

• Optimizing treatment strategies: By understanding an older adult's individual health profile, healthcare professionals can tailor treatment approaches to maximize benefits while minimizing side effects.

Treatment Considerations: Balancing Efficacy with Safety

Treatment for hematological malignancies in older adults often requires adjustments compared to younger patients. Key considerations include:

• Treatment intensity: Dose reductions or less intensive regimens may be necessary to manage potential toxicities.

• Comorbidities: The presence of other medical conditions needs careful consideration when selecting treatment options.

• Treatment tolerance: Close monitoring for adverse effects and tailoring treatment accordingly is crucial.

Conclusion

Haematological malignancies are a growing concern in older adults. Geriatric assessment and a nuanced approach to treatment are essential for optimizing outcomes in this vulnerable population. Further research on age-specific treatment strategies and supportive care remains vital to improve the lives of older adults battling blood cancers.